Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1405 plus GP chemotherapy in recurrent/metastatic nasopharyngeal carcinoma
CTR20211061Phase 3Terminated
- Sponsor
- Zhixiang Jintai
- Start
- May 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GR-1405 in nasopharyngeal carcinoma (NPC), sponsored by Zhixiang Jintai. Started May 2021; status: terminated.
02
Drugs
GR-1405
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20211061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211061.